Travere is moving from a FILSPARI-led commercial launch into a broader rare-kidney platform: FILSPARI demand is accelerating across IgAN and FSGS, while pegtibatinase is in Phase 3 for HCU and civorebrutinib expands the pipeline. The filing changes the leadership of that expansion. Bradley Campbell is contracted to become President and Chief Executive Officer on December 1, 2026, with a board seat tied to his employment. 〔0〕 〔1〕 This is a genuine new disclosure, not a routine confirmation; the filing does not provide a reason for the succession or describe outgoing CEO Eric Dube’s future role.
| Compensation element | Stated terms |
|---|---|
| Base salary | $1.0 million annually (Section 3.1) |
| Target annual bonus | 85% of base salary, or $850,000 at target (Section 3.2) |
| Initial stock option | Approximately $8.25 million (Section 3.3(a)) |
| Initial time-based RSUs | Approximately $8.25 million (Section 3.3(a)) |
| Planned 2027 performance RSUs | Approximately $3.75 million (Section 3.3(b)) |
| Expense payment | $500,000, subject to repayment in some early-departure cases (Section 4.3) |
The package is unusually substantial because it is designed to lock in a CEO for a growth-and-execution phase. The agreement provides roughly $20.25 million of stated equity value, mostly vesting over four years, alongside $1.85 million of target annual cash compensation. 〔2〕 〔3〕 〔4〕 The performance award is tied to future corporate, clinical and/or regulatory milestones, which aligns the hire with the company’s next leg of commercial and pipeline delivery rather than just maintaining the existing business.
The business impact is important but not yet measurable. Travere’s recent operating story is strong—second-quarter FILSPARI sales reached $141.1 million, up 96% year over year, with 2,012 new patient start forms—so the leadership change arrives during execution, not a turnaround. The risk is transition: Campbell inherits a company that must convert FSGS launch momentum into durable growth while funding and advancing pegtibatinase and newer pipeline assets. The filing gives no new operating targets, strategic shift, or evidence that performance has deteriorated.
Bottom line: This is a meaningful CEO succession, not a routine executive reshuffle. The large, milestone-linked package signals that Travere is hiring for the next growth phase, but the filing leaves the central question—whether Campbell can sustain current commercial momentum—unanswered.
Read the original 8-K on SEC EDGAR ↗